EHA 2026: Tacabrutideg Shows High Response Rates and Durable Outcomes in High-Risk Relapsed/Refractory CLL

Phase 1 data from CaDAnCe-101 demonstrate promising efficacy and good tolerability of tacabrutideg in heavily pretreated patients with high-risk CLL, with response rates exceeding 90% at the selected dose. In this EHA 2026 update, Stephan Stilgenbauer, MD, of Ulm University, reviews the findings and their implications for further exploration in earlier disease settings.